CERDELGA CAPSULE

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

ELIGLUSTAT (ELIGLUSTAT TARTRATE)

Mevcut itibaren:

SANOFI GENZYME, A DIVISION OF SANOFI-AVENTIS CANADA INC

ATC kodu:

A16AX10

INN (International Adı):

ELIGLUSTAT

Doz:

84MG

Farmasötik formu:

CAPSULE

Kompozisyon:

ELIGLUSTAT (ELIGLUSTAT TARTRATE) 84MG

Uygulama yolu:

ORAL

Paketteki üniteler:

14/56

Reçete türü:

Prescription

Terapötik alanı:

OTHER MISCELLANEOUS THERAPEUTIC AGENTS

Ürün özeti:

Active ingredient group (AIG) number: 0158970001; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2017-04-21

Ürün özellikleri

CERDELGA (eliglustat capsules)_ _
_ _
_ _
_Page 1 of 45_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
CERDELGA™
Eliglustat capsules
84 mg eliglustat (as eliglustat tartrate), for oral administration
Various Alimentary Tract and Metabolism Product
Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
1755 Steeles Avenue WestToronto, ON M2R 3T4
Date of Initial Authorization:
APR 21, 2017
Date of Revision:
NOV 29, 2023
Submission Control Number: 275984
RECENT MAJOR LABEL CHANGES
Not Applicable
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
4
DOSAGE AND ADMINISTRATION
..................................................................................
5
4.1
Dosing Considerations
.............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
........................................................ 5
4.4
Administration
.........................................................................................................
9
4.5
Missed Dose
............................................................................................................
9
5
OVERDOSAGE
.........................................................